Premium
FDA approves marketing of first nondrug treatment for ADHD
Author(s) -
Canady Valerie A.
Publication year - 2019
Publication title -
mental health weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7583
pISSN - 1058-1103
DOI - 10.1002/mhw.31879
Subject(s) - food and drug administration , medical prescription , attention deficit hyperactivity disorder , psychiatry , medicine , family medicine , advertising , psychology , business , pharmacology
The U.S. Food and Drug Administration (FDA) announced April 19 approval to market the first medical device to treat attention deficit hyperactivity disorder (ADHD). The prescription‐only device, called the Monarch external Trigeminal Nerve Stimulation (eTNS) System, is indicated for patients ages 7 to 12 years old who are not currently taking prescription ADHD medication.